Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
135.62B
Market cap135.62B
Price-Earnings ratio
12.64
Price-Earnings ratio12.64
Dividend yield
7.20%
Dividend yield7.20%
Average volume
51.17M
Average volume51.17M
High today
$23.99
High today$23.99
Low today
$23.64
Low today$23.64
Open price
$23.80
Open price$23.80
Volume
26.81M
Volume26.81M
52 Week high
$30.43
52 Week high$30.43
52 Week low
$20.92
52 Week low$20.92

PFE News

Simply Wall St 2d
Should You Reconsider Pfizer as Shares Fall After Latest Drug Pipeline Setback?

If you are wondering what to do with your Pfizer shares right now, you are not alone. Maybe you are eyeing the stock’s steady slide over the past year and think...

Should You Reconsider Pfizer as Shares Fall After Latest Drug Pipeline Setback?
Benzinga 3d
Pfizer Faces Court Over Depo-Provera Brain Tumor Claims

Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key c...

Pfizer Faces Court Over Depo-Provera Brain Tumor Claims
TipRanks 5d
GlaxoSmithKline Bets on Politics and U.S. Pipeline to Reclaim Pharma Prominence

British pharma contender GlaxoSmithKline (GSK) is striving to regain relevance in a field long overshadowed by its rivals Pfizer (PFE) and Merck (MRK). Renowned...

Analyst ratings

61%

of 23 ratings
Buy
34.8%
Hold
60.9%
Sell
4.3%

More PFE News

TipRanks 5d
Metsera downgraded to Market Perform from Outperform at Leerink

Leerink downgraded Metsera (MTSR) to Market Perform from Outperform with a price target of $57, down from $77, after Pfizer (PFE) announced an agreement to acqu...

TipRanks 6d
Pfizer’s Strategic Repositioning in the Obesity Market: A Buy Rating Backed by Undervalued Shares and Growth Potential

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer, with a price target of $30.00. Elevate Your Investing Strateg...

TipRanks 6d
Pfizer’s Strategic Acquisition of Metsera: A Cautious Hold Amid Market Positioning and Regulatory Uncertainty

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Pfizer yesterday and set a price target of $33.00. Elevate Your Investing Strategy: Take advant...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.